# Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

> **NCT00381836** · PHASE2,PHASE3 · TERMINATED · sponsor: **University of Aarhus** · enrollment: 140 (estimated)

## Conditions studied

- Prostatic Neoplasms
- Anemia

## Interventions

- **DRUG:** Darbepoetin Alfa

## Key facts

- **NCT ID:** NCT00381836
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 140 (ESTIMATED)
- **Why stopped:** Terminated by sponsor due to general risk that aranesp caused tumor progression
- **Last updated:** 2015-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381836, "Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00381836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*